Gilead Sciences Inc posted a 26per cent rise in quarterly revenue on Thursday, helped by sales of its antiviral drug, remdesivir, which is authorized to treat COVID-19 patients across the world.
Gilead forecasts 2021 growth, strong remdesivir COVID-19 sales
